NCT02860676View on ClinicalTrials.gov

Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

February 27, 2018

Study Completion Date

May 22, 2018

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

cirmtuzumab

cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT02860676 - Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | Biotech Hunter | Biotech Hunter